Avantor Inc is a global supplier of ultra-pure materials and integrated solutions for the life sciences and advanced technology sectors. The company supports a wide range of industries by providing high-quality products, including chemicals, reagents, and consumables, as well as laboratory services and customized solutions. Avantor's extensive portfolio is designed to enhance research and development, manufacturing processes, and quality control, helping customers accelerate innovation and improve outcomes across various applications, from pharmaceuticals to biotechnology and diagnostics. Its commitment to sustainability and operational excellence drives the company's mission to enhance scientific discovery and guide advancements in the scientific community. Read More
Shares of life sciences company Avantor (NYSE:AVTR)
jumped 6.1% in the morning session after activist investor Engine Capital disclosed it is pushing the company to explore a potential sale or make other strategic changes to boost shareholder value. In a letter to Avantor's board, activist investor Engine Capital, which revealed a 3% stake, suggested the life sciences company could be worth $17 to $19 per share in a sale. Alternatively, Engine Capital outlined recommendations, including refreshing the board and selling non-core assets, that it believes could drive the share price as high as $26 by the end of 2027. In response, Avantor reaffirmed its commitment to creating shareholder value, highlighting a $400 million cost-cutting program and a reduction in debt by nearly $1.5 billion over the last 18 months. The company also confirmed that Emmanuel Ligner is set to take over as CEO on August 18.
Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance, missed targets, and lost market share.
Avantor (NYSE: AVTR) is a global leader in providing mission-critical products and services to customers in the life sciences and advanced technology industries. Headquartered in Radnor, Pennsylvania, the company plays a pivotal role in supporting scientific innovation across diverse sectors, from biopharmaceuticals and healthcare to education and government. Avantor's extensive
Avantor (NYSE: AVTR) shares have recently experienced a significant and sustained plunge, hitting a 52-week low and reflecting a challenging period for the life sciences company. This sharp decline is a direct consequence of both a widespread market sell-off and a confluence of company-specific issues, sending ripples of concern through
Avantor missed Q2 EPS expectations as weak bioprocessing sales and customer disruptions pressured earnings, despite flat organic growth and a CEO change.
Shares of life sciences company Avantor (NYSE:AVTR)
fell 15.5% in the morning session after the company reported disappointing second-quarter results and cut its full-year financial forecast. The company’s adjusted earnings per share of $0.24 missed analyst expectations, while revenue slipped 1% to $1.68 billion. Profitability saw a sharp decline as net income fell to $64.7 million from $92.9 million in the same quarter of the previous year. The company's Laboratory Solutions division, a key revenue source, recorded a 3% drop in sales. Compounding these issues, Avantor lowered its financial projections for the full year, signaling to investors that it anticipated these headwinds would continue. The combination of missing current earnings and lowering future guidance prompted the negative investor reaction.
Avantor Inc (NYSE:AVTR) reported Q2 2025 earnings below estimates, with revenue at $1.68B and EPS of $0.24, sparking a 7.1% pre-market stock drop. Weak demand and margin pressures drove the miss.
Life sciences company Avantor (NYSE:AVTR) announced better-than-expected revenue in Q2 CY2025, but sales fell by 1.1% year on year to $1.68 billion. Its non-GAAP profit of $0.24 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Avantor (NYSE:AVTR)
fell 8% in the afternoon session after the company announced that it has appointed Emmanuel Ligner as its new President and Chief Executive Officer, effective August 18, 2025.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 8.6%. This drop was discouraging since the S&P 500 held steady.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Life sciences company Avantor (NYSE:AVTR) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 5.9% year on year to $1.58 billion. Its non-GAAP profit of $0.23 per share was in line with analysts’ consensus estimates.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Avantor (NYSE:AVTR) and the best and worst performers in the research tools & consumables industry.
